Table 4.
Mice (n = 4) injected with 50 μg of FVIII plasmid to induce anti-FVIII inhibitors
| Week after FVIII plasmid injection |
Week after anti-CD3 treatment* |
||||
|---|---|---|---|---|---|
| 1 | 4 | 8 | 2 | 4 | |
| FVIII activities, percentage of normal | |||||
| P1 | 189 | 0 | 0 | 13.3 | 11.1 |
| P2 | 258 | 0 | 0 | 155.4 | 20.5 |
| P3 | 227 | 0 | 0 | 0 | 0 |
| P4 | 304 | 0 | 0 | Died | Died |
| Anti-FVIII inhibitors, BU | |||||
| P1 | 0 | 0.3 | 0.4 | 0 | 0 |
| P2 | 0 | 50 | 62 | 0 | 3 |
| P3 | 0 | 0.3 | 1 | 0 | 0.1 |
| P4 | 0 | 45 | 88 | Died | Died |
Eight weeks after plasmid injection, mice were treated with 40 μg of anti-CD3 for 5 consecutive days. FVIII activities and anti-FVIII inhibitors were monitored before and after anti-CD3 treatment as described in “Gene transfer of FVII into hemophilia A mice with immunomodulation regimen by anti-CD3 antibodies.”
Died indicates that the mouse is deceased.
*
A 5-day course of anti-CD3 treatment was administered 8 weeks after FVIII plasmid injection treatment.